Современные стратегии в сохранении женского здоровья: междисциплинарный взгляд

1. XXV FIGO World Congress of Gynecology and Obstetrics, 5-9 October 2025. Available at: https://www.who.int/news-room/events/detail/2025/10/05/default-calendar/xxv-figo-world-congress-of-gynecology-and-obstetrics
2. Advancing women’s health: a journey of unity and freedom. Available at: https://figo2025.org/programme/?utm_source=chatgpt.com
3. A Global Rally Calling for Stronger Maternal Health: FIGO 2025 Highlights. Available at: https://laerdalglobalhealth.com/Resources/news/figo-2025-highlights/
4. World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. 2025. Available at: https://www.who.int/publications/i/item/9789240115637
5. Lamvu G., Villegas-Echeverri J.D., Allaire C., As-Sanie S., Carrillo J., Khalil S. et al. Developing the FIGO‐IPPS «RU MOVVING SOMe» classification system for female chronic pelvic pain. Int. J. Gynecol. Obstet. 2025; 171(2): 550-65. https://dx.doi.org/10.1002/ijgo.70522
6. Chronic pelvic pain: ACOG Practice Bulletin, number 218. Obstet. Gynecol. 2020; 135(3): e98-e109. https://dx.doi.org/10.1097/AOG.0000000000003716
7. Rice K., Connoy L., Webster F. Gendered worlds of pain: women, marginalization, and chronic pain. J. Pain. 2024; 25(11): 104626. https://dx.doi.org/10.1016/j.jpain.2024.104626
8. Villegas-Echeverri J.D., Robert M., Carrillo J.F., Green I., Meinhold-Heerlein I., Attar R. et al. FIGO–IPPS consensus statement: addressing the global unmet needs of women with chronic pelvic pain. Int. J. Gynecol. Obstet. 2025; 169(3): 1140-5. https://dx.doi.org/10.1002/ijgo.70093
9. Kingsberg S., Banks V., Caetano C., Janssenswillen C., Moeller C., Schoof N. et al. Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: findings from the REALISE study. Maturitas. 2024; 189: 108096. https://dx.doi.org/10.1016/j.maturitas.2024.108096
10. Pinkerton J.V., Simon J.A., Joffe H., Maki P.M., Nappi R.E., Panay N. et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024; 332(16): 1343-54. https://dx.doi.org/10.1001/jama.2024.14618
11. Gurunanselage Don R.A.S., Yap M.K.K. Arctium lappa L. root extract induces cell death via mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells. Biomed. Pharmacother. 2019; 110: 918-29. https://dx.doi.org/10.1016/j.biopha.2018.12.023
12. Zhang B., Li M., Qiao Y., Gao P, Li L., Zheng Z. Potential use of low-field nuclear magnetic resonance to determine the drying characteristics and quality of Arctium lappa L. in hot-blast air. LWT. 2020; 132: 109829. https://dx.doi.org/10.1016/j.lwt.2020.109829
13. Lee J., Ha S.J., Park J., Kim Y.H., Lee N.H., Kim Y.E. et al. Arctium lappa root extract containing L-arginine prevents TNF-α-induced early atherosclerosis in vitro and in vivo. Nutr. Res. 2020; 77: 85-96. https://dx.doi.org/10.1016/j.nutres.2020.03.003
14. Andritoiu C.V., Andriescu C.E., Ibanescu C., Lungu C., Ivanescu B., Vlase L. et al. Effects and characterization of some topical ointments based on vegetal extracts on incision, excision, and thermal wound models. Molecules. 2020; 25(22): 5356. https://dx.doi.org/10.3390/molecules25225356
15. Tobyn G., Denham A., Whitelegg M. Arctium lappa, burdock. 2011; 91-103. In: Medical Herbs. https://dx.doi.org/10.1016/B978-0-443-10344-5.00015-X
16. Miglani A., Manchanda R.K. Observational study of Arctium lappa in the treatment of acne vulgaris. Homeopathy. 2014; 103(3): 203-7. https://dx.doi.org/10.1016/j.homp.2013.12.002
17. Yosri N., Alsharif S.M., Xiao J., Musharraf S.G., Zhao C., Saeed A. et al. Arctium lappa (Burdock): insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine. Biomed. Pharmacotherapy. 2023; 158: 114104. https://dx.doi.org/10.1016/j.biopha.2022.114104
18. Moro T.M.A., T P S Clerici M. Burdock (Arctium lappa L) roots as a source of inulin-type fructans and other bioactive compounds: current knowledge and future perspectives for food and non-food applications. Food Res. Int. 2021; 141: 109889. https://dx.doi.org/10.1016/j.foodres.2020.109889
19. García-Gamboa R., Domínguez-Simi M.Á., Gradilla-Hernández M.S., Bravo-Madrigal J., Moya A., González-Avila M. Antimicrobial and antibiofilm effect of inulin-type fructans, used in synbiotic combination with Lactobacillus spp. against candida albicans. Plant Foods Hum. Nutr. 2022; 77(2): 212-9. https://dx.doi.org/10.1007/s11130-022-00966-3
20. García-Gamboa R., Domínguez-Simi M., Gradilla-Hernández M.S., Bravo J., Moya A., Ruiz-Álvarez B. et al. Anticandidal and antibiofilm effect of synbiotics including probiotics and inulin-type fructans. Antibiotics (Basel). 2022; 11(8): 1135. https://dx.doi.org/10.3390/antibiotics11081135
21. Aehle E., Müller U., Eklund P.C., Willför S.M., Sippl W., Dräger B. Lignans as food constituents with estrogen and antiestrogen activity. Phytochemistry. 2011; 72(18): 2396-405. https://dx.doi.org/0.1016/j.phytochem.2011.08.013
22. Burgberger M, Mierziak J, Augustyniak B, Wojtasik W, Kulma A. The power of lignans: plant compounds with multifaceted health-promoting effects. Metabolites. 2025; 15(9): 589. https://dx.doi.org/10.3390/metabo15090589
23. Parish S.J., Simon J.A., Davis S.R., Giraldi A., Goldstein I., Goldstein S.W. et al. International society for the study of women’s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J. Sex. Med. 2021; 18(5): 849-67. https://dx.doi.org/10.1016/j.jsxm.2020.10.009
24. Clayton A.H., Kingsberg S.A., Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sex. Med. 2018; 6(2): 59-74 https://dx.doi.org/10.1016/j.esxm.2018.01.004
25. Parish S.J., Cottler-Casanova S., Clayton A.H., McCabe M.P., Coleman E., Reed G.M. The evolution of the female sexual disorder / dysfunction definitions, nomenclature, and classifications: a review of DSM, ICSM, ISSWSH, and ICD. Sex. Med. Rev. 2021; 9(1): 36-56. https://dx.doi.org/10.1016/j.sxmr.2020.05.001
26. Taranto P., de Brito Sales D., Maluf F.C., Guendelmann R.A.K., de Melo Pompei L., Leal A. Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy. Breast Cancer Res. 2024; 26(1): 133. https://dx.doi.org/10.1186/s13058-024-01886-7
27. Eapen R.S., Radomski S.B. Gender differences in overactive bladder. Can. J. Urol. 2016; 23(Suppl 1): 2-9.
28. Russo E., Caretto M., Giannini A., Bitzer J., Cano A., Ceausu I. et al. Management of urinary incontinence in postmenopausal women: an EMAS clinical guide. Maturitas. 2021; 143: 223-30. https://dx.doi.org/10.1016/j.maturitas.2020.09.005
29. Cho S.T., Kim K.H. Pelvic floor muscle exercise and training for coping with urinary incontinence. J. Exerc. Rehabil. 2021; 17(6): 379-87. https://dx.doi.org/10.12965/jer.2142666.333
30. NICE Guidance – Urinary incontinence and pelvic organ prolapse in women: management: ©NICE (2019) Urinary incontinence and pelvic organ prolapse in women: management. BJU Int. 2019; 123(5): 777-803. https://dx.doi.org/10.1111/bju.14763
31. Kobashi K.C., Vasavada S., Bloschichak A., Hermanson L., Kaczmarek J., Kim S.K. et al. Updates to surgical treatment of female stress urinary incontinence (SUI): AUA/SUFU Guideline. J. Urol. 2023; 209(6). 1091-8. https://dx.doi.org/10.1097/JU.0000000000003435
32. Yao H., Zhang X., Sun F., Tang G., Wu J., Zhou Z. The efficacy of intravaginal electrical stimulation (IVES) in treating female with urinary incontinence symptom from meta-analysis of nine randomized controlled trials. Front. Neurol. 2022; 13: 933679. https://dx.doi.org/10.3389/fneur.2022.933679
33. Cameron A.P., Chung D.E., Dielubanza E.J., Enemchukwu E., Ginsberg D.A., Helfand B.T. et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J. Urol. 2024; 212(1): 11-20. https://dx.doi.org/10.1097/JU.0000000000003985
34. Webber L., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016; 31(5): 926-37. https://dx.doi.org/10.1093/humrep/dew027
35. Li M., Zhu Y., Wei J., Chen L., Chen S., Lai D. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023; 26(2): 95-102. https://dx.doi.org/10.1080/13697137.2022.2153033
36. Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. ESHRE, Evidence-based guideline: premature ovarian insufficiency. Hum. Reprod. Open. 2024; 2024(4): hoae065. https://dx.doi.org/10.1093/hropen/hoae065
37. Chon S.J., Umair Z., Yoon M.S. Premature ovarian insufficiency: past, present, and future. Front. Cell Dev. Biol. 2021; 9: 672890. https://dx.doi.org/10.3389/fcell.2021.672890
38. Xi D., Chen B., Tao H., Xu Y., Chen G. The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency: a systematic review and meta-analysis. Arch. Womens Ment Health. 2023; 26(1): 1-10. https://dx.doi.org/10.1007/s00737-022-01289-7
39. McDonald I.R., Welt C.K., Dwyer A.A. Health-related quality of life in women with primary ovarian insufficiency: a scoping review of the literature and implications for targeted interventions. Hum. Reprod. 2022; 37(12): 2817-30. https://dx.doi.org/10.1093/humrep/deac200
40. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://dx.doi.org/10.1097/GME.0000000000001609
41. Carlson K., Nguyen H. Genitourinary syndrome of menopause. In: StatPearls
42. Kapoor E. Premature ovarian insufficiency. Curr. Opin. Endocr. Metab. Res. 2023; 28: 100435. https://dx.doi.org/10.1016/j.coemr.2023.100435
43. European Society of Human Reproduction and Embryology. Guideline on premature ovarian insufficiency. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Premature-ovarian-insufficiency
44. Calik-Ksepka A., Grymowicz M., Rudnicka E., Skórska J., Machura P., Pięta W. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Prz. Menopauzalny. 2018; 17(3): 131-4. https://dx.doi.org/10.5114/pm.2018.78558
45. Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International menopause society white paper. Climacteric. 2020; 23(5): 426-46. https://dx.doi.org/10.1080/13697137.2020.1804547
46. British Menopause Society. BMS Consensus Statement. Premature ovarian insufficiency POI. Available at: https://thebms.org.uk/wp-content/uploads/2024/04/05-BMS-ConsensusStatement-Premature-ovarian-insufficiency-POI-APRIL2024-C.pdf
47. Palacios S., Nappi R.E., Bruyniks N., Particco M., Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018; 21(3): 286-91. https://dx.doi.org/10.1080/13697137.2018.1446930
48. Nappi R.E., Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014; 17(1): 3-9. https://dx.doi.org/10.3109/13697137.2013.871696
49. Vazirani A., Ravichandiran N. Prevalence of menopausal symptoms and their health seeking behavior in postmenopausal women in a tertiary care hospital. J. Obstet. Gynecol. Cancer Res. 2024; 9(4): 385-94.
50. Palacios S. Sequential treatment in vulvovaginal atrophy. Climacteric. 2023; 26(4): 292-5. https://dx.doi.org/10.1080/13697137.2023.2197588
51. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025. Доступно по: https://drive.google.com/file/d/143g7Dfbg5-EpnCwRfNarLPNIH_X7LItw/view
52. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Аменорея и олигоменорея. 2024. Доступно по: https://cr.minzdrav.gov.ru/view-cr/644_2
53. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Остеопороз. 2021. Доступно по: https://legalacts.ru/doc/klinicheskie-rekomendatsii-osteoporoz-utv-minzdravom-rossii/

Поступила 04.02.2026

Принята в печать 13.02.2026